All Posts

Following our latest portfolio update, a few companies appeared across multiple BPIQ portfolios. Since Top 10A, Top 10B, and Top 15 use different portfolio construction approaches, many stocks appear in only one portfolio. When a company appears across multiple portfolios, it suggests that it ranks highly across multiple versions of our hedge fund consensus framework. Examples from the latest update: DYN → included in Top 10A, Top 10B, and Top 15 ORIC → included in Top 10A an

With the latest hedge fund filings incorporated into our portfolio targets, many subscribers ask a similar question: Why does BPIQ maintain multiple portfolio strategies instead of a single portfolio? The answer is simple. While all of our core portfolios are built from the same foundation, top holdings and consensus positions of biotech-focused hedge funds, portfolio construction matters. As discussed in our recent blog, consensus is the signal, structure is the edge. Years

The new holding targets for our three quarterly-adjusted BPIQ model portfolios, Top10A, Top15, and Top10B, have now been updated. Elite and APEX subscribers can view the latest portfolio targets here: 👉 https://app.bpiq.com/model-portfolios/hf-targets You can also track quarter-over-quarter changes, including stocks that were added or removed, along with their percentage change based on the latest update as of 5/16/26: 👉 https://app.bpiq.com/model-portfolios/hf-targets-chan

Biotech investing is not limited by access to information.It is limited by the ability to make consistently better decisions in a highly uncertain environment. Even deep diligence and strong science often fail to translate into consistent outcomes. This led us to shift away from picking individual winners and toward understanding how experienced biotech investors allocate capital. One pattern stood out: Companies held across multiple top biotech-focused hedge funds tend to ou

Dyne Therapeutics is our May 2026 Hedge Fund Favorite Spotlight, with strong institutional interest, a differentiated neuromuscular pipeline, and upcoming catalyst potential. DYN was held by 13 of 34 biotech-focused hedge funds in Q4 2025, placing it well above the typical median holding level across the group. The company’s lead program, DYNE-251, is being advanced for Duchenne muscular dystrophy and is expected to reach BLA submission milestone in Q2 2026. From an investor

At AACR 2026, several first-time disclosed oncology programs highlighted how public biotech and pharma companies are positioning for the next wave of innovation. From an investor perspective, the key question remains: Does this asset improve the company’s position in a real, competitive market? Below is a focused look at newly disclosed assets from public companies, through four lenses: disease target, competition, technology, and potential market impact. 🟢 AstraZeneca: Prec

Biotech investing is not limited by access to information. It is limited by the ability to pick winning stocks and winning portfolio strategies. Even with strong science and data, consistent outperformance is difficult to achieve for any individual investor or investment group. With an investing background in biotech dating back to the late 1990s, we have seen that deep diligence by even a very experienced biotech pro on individual companies still often leads to disappointing

Q4 13F filings are now available.

Summary

Summary